What is HC Wainwright’s Estimate for CRVS Q4 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright issued their Q4 2024 EPS estimates for Corvus Pharmaceuticals in a research report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.49 EPS.

Several other analysts also recently issued reports on the company. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ CRVS opened at $5.43 on Friday. The company has a market capitalization of $348.92 million, a price-to-earnings ratio of -5.84 and a beta of 1.05. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00. The firm has a 50-day moving average of $7.72 and a two-hundred day moving average of $5.26.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals in the second quarter valued at about $44,000. Nwam LLC bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. XTX Topco Ltd acquired a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at $74,000. Virtu Financial LLC acquired a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at about $83,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $89,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.